Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line

被引:0
|
作者
Kohara, H [1 ]
Tabata, M [1 ]
Kiura, K [1 ]
Ueoka, H [1 ]
Kawata, K [1 ]
Chikamori, M [1 ]
Aoe, K [1 ]
Chikamori, K [1 ]
Matsushita, A [1 ]
Harada, M [1 ]
机构
[1] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7-ethyl-10-[4-(1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, a topoisomerase I (topo I) inhibitor, is one of the most active agent against lung cancer, and its radiosensitizing effect has been reported recently. We evaluated a combination in vitro effect of irradiation and 7-ethyl-10-hydroxy-CPT (SN-38), an active metabolite of 7-ethyl-10-[4- (1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, on a human small cell lung cancer cell line (SBC-3) and its cisplatin-resistant subline (SBC-3/CDDP). Growth-inhibitory effects of irradiation with or without SN-38 were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A modified isobologram method was used to evaluate the treatment interaction. The combination of irradiation and SN-38 showed a synergistic inhibitory effect on the growth of SBC-3/CDDP despite its cross-resistance to irradiation and SN-38. In contrast, the same combination showed only an additive effect on the growth of parental SBC-3 cells. There was no significant difference in topo I protein expression between these two cell lines. In SBC-3 cells, topo I catalytic activity was suppressed by 4 Gy of irradiation, without a decrease of nuclear topo I protein, whereas the exposure of SBC-3 cells to 1 muM SN-38 subsequent to irradiation showed no remarkable additional effects on both topo I activity and protein content. On the other hand, in SBC-3/CDDP cells, topo I activity was unchanged by irradiation, but the subsequent exposure to SN-38 gave rise to a decrease in topo I activity, which was accompanied by a significant decrease in the topo I protein content (P = 0.02). These observations may indicate that SN-38 induces sequestration of topo I onto DNA in radiation-treated SBC-3/CDDP cells and suggest that the synergistic effect of irradiation and SN-38 in SBC-3/CDDP cells was considered attributable to DNA repair-related enhanced recruitment of topo I onto the damaged DNA.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 50 条
  • [1] 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
    Wang, Airong
    Li, Lingling
    Li, Mengya
    Wang, Shujuan
    Wang, Chong
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] Case Report: 7-Ethyl-10-Hydroxycamptothecin, a DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
    Wang, Airong
    Li, Lingling
    Li, Mengya
    Wang, Shujuan
    Wang, Chong
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids
    Moritaka, T
    Kiura, K
    Ueoka, H
    Tabata, M
    Segawa, Y
    Shibayama, T
    Takigawa, N
    Ohnoshi, T
    Harada, M
    ANTICANCER RESEARCH, 1998, 18 (2A) : 927 - 933
  • [4] Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line
    Chikamori, M
    Takigawa, N
    Kiura, K
    Tabata, M
    Shibayama, T
    Segawa, Y
    Ueoka, H
    Ohnoshi, T
    Tanimoto, M
    ANTICANCER RESEARCH, 2004, 24 (06) : 3911 - 3916
  • [5] An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line
    Kiura, K
    Watarai, S
    Ueoka, H
    Tabata, M
    Gemba, KI
    Aoe, K
    Yamane, H
    Yasuda, T
    Harada, M
    ANTICANCER RESEARCH, 1998, 18 (4C) : 2957 - 2960
  • [6] Enhanced topoisomerase I activity and increased topoisomerase IIα content in cisplatin-resistant cancer cell lines
    Minagawa, Y
    Kigawa, J
    Irie, T
    Kanamori, Y
    Itamochi, H
    Cheng, XS
    Terakawa, N
    JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (12): : 1218 - 1223
  • [7] DETERMINANTS OF DRUG RESPONSE IN A CISPLATIN-RESISTANT HUMAN LUNG-CANCER CELL-LINE
    FUJIWARA, Y
    SUGIMOTO, Y
    KASAHARA, K
    BUNGO, M
    YAMAKIDO, M
    TEW, KD
    SAIJO, N
    JAPANESE JOURNAL OF CANCER RESEARCH, 1990, 81 (05): : 527 - 535
  • [8] Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells
    Wang, Huan
    Zhu, Xiaoli
    Huang, Jing
    Chen, Pingsheng
    Han, Shuhua
    Yan, Xing
    ONCOLOGY LETTERS, 2016, 11 (04) : 2566 - 2572
  • [9] HYPERTHERMIC POTENTIATION OF CISPLATIN TOXICITY IN A HUMAN SMALL-CELL LUNG-CARCINOMA CELL-LINE AND A CISPLATIN-RESISTANT SUBLINE
    HETTINGA, JVE
    LEMSTRA, W
    MEIJER, C
    MULDER, NH
    KONINGS, AWT
    DEVRIES, EGE
    KAMPINGA, HH
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1994, 10 (06) : 795 - 805
  • [10] Ferroptosis as a Potential Cell Death Mechanism Against Cisplatin-Resistant Lung Cancer Cell Line
    Golbashirzadeh, Morteza
    Heidari, Hamid Reza
    Talebi, Mehdi
    Khosroushahi, Ahmad Yari
    ADVANCED PHARMACEUTICAL BULLETIN, 2023, 13 (01) : 176 - 187